We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.21 | -4.41% | 4.55 | 4.54 | 4.61 | 4.94 | 4.475 | 4.94 | 5,271,344 | 00:43:38 |
Presentation details are as follows:
Date and time: Wednesday, January 9, 3:00 p.m. – 3:25 p.m. P.T.Location: Colonial Room, Westin St. Francis Hotel, San FranciscoLive webcast: www.novavax.com, “Investors”/“Events”
A replay of the presentation will also be accessible under the “Investors/Events” section of the website at www.novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu™, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
InvestorsNovavax, Inc.Erika Trahanir@novavax.com240-268-2000
Westwicke PartnersJohn Woolfordjohn.woolford@westwicke.com443-213-0506
MediaSam BrownAndrea Cohenandreacohen@sambrown.com917-209-7163
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions